专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20210355106A1 NEW AMINO-PYRIMIDONYL-PIPERIDINYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM 有权
公开(公告)号：US20210355106A1
公开(公告)日：2021-11-18
申请号：US17282898
申请日：2019-10-18
申请人： LES LABORATOIRES SERVIER , VERNALIS (R&D) LTD
发明人： Csaba WÉBER , András KOTSCHY , Attila VASAS , Árpád KISS , Balázs MOLNÁR , Andrea FIUMANA , Alba MACIAS , James Brooke MURRAY , Didier DEMARLES , Lisa IVANSCHITZ , Olivier GENESTE , Kristóf HEGEDÜS , Péter SPRÁNITZ , Tibor SOÓS
IPC分类号： C07D401/14 , A61P35/00 , A61K45/06 , A61K31/513 , C07D417/14 , A61K31/517 , C07D409/14 , C07D405/14
摘要： wherein R1, R2, R3, R4, R5, n and Q are as defined in the description.

2. 发明授权

US10689364B2 Isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them 有权
公开(公告)号：US10689364B2
公开(公告)日：2020-06-23
申请号：US15704330
申请日：2017-09-14
申请人： LES LABORATOIRES SERVIER , VERNALIS (R&D) LTD
发明人： James Edward Paul Davidson , James Brooke Murray , I-Jen Chen , Claire Walmsley , Mark Dodsworth , Johannes W. G. Meissner , Paul Brough , Imre Fejes , János Tatai , Miklós Nyerges , András Kotschy , Zoltán Szlávik , Olivier Geneste , Arnaud Le Tiran , Thierry Le Diguarher , Jean-Michel Henlin , Jérôme-Benoît Starck , Anne-Françoise Guillouzic , Guillaume De Nanteuil
IPC分类号： C07D401/14 , C07D405/14 , A61K31/4725 , C07D409/14 , C07D471/04 , A61K31/496 , A61K31/497 , A61K31/5377 , A61K31/675 , A61K45/06 , A61N5/10 , C07D417/14 , C07F9/6561
摘要： Compounds of formula (I): wherein Het, R3, R4, R5, R7, R8, R9, T, p, p′, q, and q′ are as defined in the description. Medicinal products containing the same which are useful in treating conditions requiring a pro-apoptotic agent.

3. 发明授权

US10258626B2 Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them 有权
公开(公告)号：US10258626B2
公开(公告)日：2019-04-16
申请号：US15428493
申请日：2017-02-09
申请人： LES LABORATOIRES SERVIER , VERNALIS (R&D) LTD
发明人： Thierry Le Diguarher , Patrick Casara , Jérôme-Benoît Starck , Jean-Michel Henlin , James Edward Paul Davidson , James Brooke Murray , Christopher John Graham , I-Jen Chen , Olivier Geneste , John Hickman , Stéphane Depil , Arnaud Le Tiran , Mikl{dot over (o)}s Nyerges , Guillaume De Nanteuil
IPC分类号： A61K31/55 , A61K31/475 , A61K31/496 , A61K31/541 , A61K31/553 , A61K31/4725 , A61K31/5377 , A61K31/5383 , C07D491/052 , C07D401/02 , C07D401/12 , A61N5/10 , C07D471/00 , C07D471/04 , C07D487/04 , C07D207/30 , C07D211/06 , C07D211/80 , A61K45/06 , C07D498/04
摘要： Compounds of formula (I): wherein Ra, Rb, Rc, Rd, R1, R2, R3, R4, R5, X, Y and Het are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

4. 发明授权

US09718793B2 Isoxazole compounds as inhibitors of heat shock proteins 有权
公开(公告)号：US09718793B2
公开(公告)日：2017-08-01
申请号：US13929098
申请日：2013-06-27
申请人： Vernalis (R&D) Limited , Cancer Research Technology Limited , The Institute of Cancer Research
发明人： Martin James Drysdale , Brian William Dymock , Harry Finch , Paul Webb , Edward McDonald , Karen Elizabeth James , Kwai Ming Cheung , Thomas Peter Matthews
IPC分类号： C07D261/08 , C07D261/10 , C07D495/04 , C07D413/10 , C07D413/04 , C07D417/14 , C07D417/04
CPC分类号： A61K31/541 , A61K31/42 , A61K31/422 , A61K31/427 , A61K31/4439 , A61K31/454 , A61K31/4709 , A61K31/496 , A61K31/5377 , C07D261/08 , C07D261/10 , C07D413/04 , C07D413/10 , C07D417/04 , C07D495/04
摘要： Isoxazoles of formula (A) or (B) are inhibitors of HSP90 activity, and useful for treatment of, for example cancers: wherein R1, is a group of formula (IA): —Ar1-(Alk1)p-(Z)r-(Alk2)s-Q, wherein in any compatible combination Ar1 is an optionally substituted aryl or heteroaryl radical, Alk1 and Alk2 are optionally substituted divalent C1-C6 alkylene or C2-C6 alkenylene radicals, p, r and s are independently 0 or 1, Z is —O—, —S—, —(C═O)—, —(C═S)—, —SO.sub.2-, —C(═O)O—, —C(═O)NRA—, —C(═S)NRA—, —SO2NRA—, —NRAC(═O)—, —NRASO2— or —NRA— wherein RA is hydrogen or C1-C6 alkyl, and Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical; R2 is (i) a group of formula (IA) above or (ii) a carboxamide radical; or (iii) a non aromatic carbocyclic or heterocyclic ring wherein a ring carbon is optionally substituted, and/or a ring nitrogen is optionally substituted by a group of formula -(Alk1)p-(Z)r-(Alk2)s-Q wherein Q, Alk1, Alk2, Z, p, r and s are as defined above in relation to group (IA); and R3 is hydrogen, optionally substituted cycloalkyl, cycloalkenyl, C1-C6 alkyl, C1-C6 alkenyl, or C1-C6 alkynyl; or a carboxyl, carboxamide, or carboxyl ester group.

5. 发明授权

US09670227B2 Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them 有权
公开(公告)号：US09670227B2
公开(公告)日：2017-06-06
申请号：US14576683
申请日：2014-12-19
申请人： LES LABORATOIRES SERVIER , VERNALIS (R&D) LIMITED
发明人： András Kotschy , Zoltán Szlávik , Márton Csékei , Attila Paczal , Zoltán Szabó , Szabolcs Sipos , Gábor Radics , Ágnes Proszenyák , Balázs Bálint , Alain Bruno , Olivier Geneste , James Edward Paul Davidson , James Brooke Murray , I-Jen Chen , Françoise Perron-Sierra
IPC分类号： C07D239/00 , C07D333/00 , C07D495/04 , A61K31/519 , A61K31/5377 , A61K31/538 , A61K31/55 , A61K45/06 , A61N5/10
CPC分类号： A61K31/519 , A61K31/5377 , A61K31/538 , A61K31/55 , A61K45/06 , A61N5/10 , C07D495/04
摘要： Compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R12, X, A and n are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

6. 发明授权

US09610290B2 Thienopyrimidine compounds 有权
公开(公告)号：US09610290B2
公开(公告)日：2017-04-04
申请号：US14803214
申请日：2015-07-20
申请人： Vernalis (R&D) Ltd.
发明人： Allan Jordan , Simon Bedford , Klenke Burkhard , Ian Yule , Karine Poullennec
IPC分类号： A61K31/519 , C07D495/04
CPC分类号： C07D495/04 , A61K31/519 , C07D495/14
摘要： Compounds of formula (I) are A2B receptor antagonists: Wherein R1 is optionally substituted aryl or an optionally substituted 5- or 6-membered heteroaryl ring; R2 and R3 are independently selected from hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl-(C1-C6)-alkyl, aryl-(C1-C6)-alkyl optionally substituted in the ring part thereof, a 5- or 6-membered monocyclic heterocyclic group optionally linked via a C1-C6 alkylene chain and optionally substituted in the ring part thereof, benzimidazol-2-yl-methyl, pyrid-3-yl-carbonyl, or (1-methyl-piperidin-4-yl)-carbonyl-methyl; or R2 and R3 taken together with the nitrogen atom to which they are attached form an optionally substituted 5- or 6-membered ring; R4 is C1-C3 alkyl, C2-C3 alkenyl, —(—R5)—R6, or optionally substituted heteroarylmethylamino; and R5 and R6 are independently selected from hydrogen or C1-C3 alkyl; or R5 and R6 taken together with the nitrogen atom to which they are attached form an optionally substituted 4- to 6-membered saturated ring.

7. 发明授权

US09393248B1 Aminopyridine derived compounds as LRRK2 inhibitors 有权
标题翻译：氨基吡啶衍生化合物作为LRRK2抑制剂
公开(公告)号：US09393248B1
公开(公告)日：2016-07-19
申请号：US15071955
申请日：2016-03-16
申请人： H. Lundbeck A/S , Vernalis (R&D) Ltd.
发明人： Gitte Kobberøe Mikkelsen , Laurent David , Stephen Watson , Garrick Paul Smith , Douglas Stewart Williamson , I-Jen Chen
IPC分类号： A61K31/5377 , A61K31/4439 , A61K31/4545 , A61K31/497
CPC分类号： A61K31/5377 , A61K31/4439 , A61K31/4545 , A61K31/497 , C07D401/04 , C07D401/14 , C07D403/14 , C07D413/04 , C07D413/14
摘要： The present invention is directed to aminopyridine derived compounds of formula (A) The compounds are considered useful for the treatment of diseases associated with LRRK2 such as a Lewy body dementia, Parkinson's disease or cancer.
摘要翻译：本发明涉及衍生自式（A）的氨基吡啶衍生化合物。该化合物被认为可用于治疗与LRRK2相关的疾病，例如路易体痴呆，帕金森病或癌症。

8. 发明申请

US20100305143A1 PYRROLOPYRIMIDINE COMPOUNDS 审中-公开
标题翻译：吡咯烷酮化合物
公开(公告)号：US20100305143A1
公开(公告)日：2010-12-02
申请号：US12677919
申请日：2008-09-19
申请人： Allan Jordan , Simon Bedford , Klenke Burkhard , Ian Yule , Karinne Poullennec
发明人： Allan Jordan , Simon Bedford , Klenke Burkhard , Ian Yule , Karinne Poullennec
IPC分类号： A61K31/519 , C07D487/04 , A61P29/00 , A61P3/10 , A61P35/00 , A61P11/06 , A61P11/00
CPC分类号： C07D487/04
摘要： Compounds of formula (I) are A2B receptor antagonists: wherein Ri is optionally substituted aryl or an optionally substituted monocyclic heteroaryl group having 5 or 6 ring atoms; R2 and R3 are independently selected from hydrogen, or optionally substituted C1-C6 alkyl, C1-C6 alkoxy-(C1-C6)-alkyl, C3-C8 cycloalkyl, aryl, heteroaryl, aryl-(C1-C6)-alkyl, or heteroaryl-(C1-C6)-alkyl; R4 and R5 are independently selected from hydrogen, optionally substituted C1-C6alkyl, optionally substituted aryl, aryl-(C1-C6)-alkyl optionally substituted in the ring part thereof, —NHR7—N(—R8)—R9, —NH—(C═O)—R10, —(C═O)—NH—R11, —(C═O)—O—R12, or halo; R6 is hydrogen, C1-C6 alkyl, aryl-(C1-C6)-alkyl, —(C═O)—NH—R13, —(C═O)—R14, aryl, heteroaryl, hydroxy-(C1-C6)-alkyl, or C3-C8 cycloalkyl-alkyl; and R7, R8, R9, R10, R11, R12, R13 and R14 are independently selected from C1-C6 alkyl, aryl, aryl-(C1-C6)-alkyl and heteroaryl.
摘要翻译：式（I）化合物是A2B受体拮抗剂：其中R 1是任选取代的芳基或具有5或6个环原子的任选取代的单环杂芳基; R 2和R 3独立地选自氢或任选取代的C 1 -C 6烷基，C 1 -C 6烷氧基 - （C 1 -C 6） - 烷基，C 3 -C 8环烷基，芳基，杂芳基，芳基 - （C 1 -C 6） - 烷基或杂芳基 - （C 1 -C 6） - 烷基; R 4和R 5独立地选自氢，任选取代的C 1 -C 6烷基，任选取代的芳基，在其环部任选取代的芳基 - （C 1 -C 6） - 烷基，-NHR 7 -N（-R 8）-R 9，-NH- （C = O）-R 10， - （C = O）-NH-R 11， - （C = O）-O-R 12或卤素; R6是氢，C1-C6烷基，芳基 - （C1-C6） - 烷基， - （C = O）-NH-R13， - （C = O）-R14，芳基，杂芳基，羟基 - （C1-C6） - 烷基或C 3 -C 8环烷基 - 烷基; 并且R 7，R 8，R 9，R 10，R 11，R 12，R 13和R 14独立地选自C 1 -C 6烷基，芳基，芳基 - （C 1 -C 6） - 烷基和杂芳基。

9. 发明公开

US20240150293A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS 审中-公开
公开(公告)号：US20240150293A1
公开(公告)日：2024-05-09
申请号：US18262231
申请日：2022-01-11
申请人： LES LABORATOIRES SERVIER , VERNALIS (R&D) LTD
发明人： Stephen STOKES , Simon BEDFORD , l-Jen CHEN , James Edward Paul DAVIDSON , Nicholas DAVIES , Christopher John GRAHAM , Sean Martin MCKENNA , Johannes W.G. MEISSNER , James Brooke MURRAY , Rachel Jane PARSONS , Stuart RAY , Emma SANDERS , Claire Louise WALMSLEY , Paul Andrew BROUGH , András KOTSCHY , Ágnes PROSZENYÁK , Ádám SINAI , Balázs Károly BÁLINT , Márton CSÉKEI , Márton ZWILLINGER , Rita GARAMVÖLGYI , Szabolcs SIPOS , Vilibald KUN , Zoltán SZABÓ , Maïa CHANRION , Francesca ROCCHETTI , Frédéric COLLAND , Ana Leticia MARAGNO , Laura BRESSON
IPC分类号： C07D215/233 , A61K45/06 , A61P35/00 , C07C229/50 , C07D317/70 , C07D401/12 , C07D405/10 , C07D491/056
CPC分类号： C07D215/233 , A61K45/06 , A61P35/00 , C07C229/50 , C07D317/70 , C07D401/12 , C07D405/10 , C07D491/056
摘要： Compounds of Formula (I):

wherein R1, R3, R11, R12, X, Y1, Y2, Y3, Y4 and are as defined in the description. Medicinal products containing the same which are useful in treating conditions requiring anti-apoptotic inhibitors.

10. 发明授权

US11234987B2 Isoxazole compounds as inhibitors of heat shock proteins 有权
公开(公告)号：US11234987B2
公开(公告)日：2022-02-01
申请号：US16528278
申请日：2019-07-31
申请人： Vernalis (R&D) Ltd. , The Institute of Cancer Research , Cancer Research Technology Limited
发明人： Martin James Drysdale , Brian William Dymock , Harry Finch , Paul Webb , Edward McDonald , Karen Elizabeth James , Kwai Ming Cheung , Thomas Peter Matthews
IPC分类号： A61P25/14 , A61P25/28 , A61P17/06 , A61P17/00 , A61P9/10 , A61P15/00 , A61P43/00 , A61P25/00 , A61P3/10 , A61P35/00 , A61P19/02 , A61P29/00 , A61P27/02 , A61P11/06 , A61P1/00 , C07D495/04 , C07D261/10 , C07D261/08 , C07D417/04 , C07D413/04 , C07D413/10 , A61K31/42 , A61K31/4439 , A61K31/427 , A61K31/541 , A61K31/4709 , A61K31/496 , A61K31/5377 , A61K31/454 , A61K31/422 , A61P31/12
摘要： Isoxazoles of formula (A) or (B) are inhibitors of HSP90 activity, and useful for treatment of, for example cancers: wherein R1, is a group of formula (IA): —Ar1-(Alk1)p-(Z)r-(Alk2)s-Q, wherein in any compatible combination Ar1 is an optionally substituted aryl or heteroaryl radical, Alk1 and Alk2 are optionally substituted divalent C1-C6 alkylene or C2-C6 alkenylene radicals, p, r and s are independently 0 or 1, Z is -0-, —S—, —(C═O)—, —(C═S)—, —SO.sub.2-, —C(═O)O—, —C(═O)NRA—, —C(═S) NRA—, —SO2NRA—, —NRAC(═O)—, —NRASO2— or —NRA— wherein RA is hydrogen or C1-C6 alkyl, and Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical; R2 is (i) a group of formula (IA) above or (ii) a carboxamide radical; or (iii) a non aromatic carbocyclic or heterocyclic ring wherein a ring carbon is optionally substituted, and/or a ring nitrogen is optionally substituted by a group of formula -(Alk1)p-(Z)r-(Alk2)s-Q wherein Q, Alk1, Alk2, Z, p, r and s are as defined above in relation to group (IA); and R3 is hydrogen, optionally substituted cycloalkyl, cycloalkenyl, C1-C6 alkyl, C1-C6 alkenyl, or C1-C6 alkynyl; or a carboxyl, carboxamide, or carboxyl ester group.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式